FrancophonIA/ELRC3.0 huggingface dataset:
English: All these data were considered sufficient to conclude that Ziextenzo will behave in the same way as Neulasta in terms of effectiveness and safety in its authorised uses.
Croatian: Svi ti podatci smatraju se dovoljnima za donošenje zaključka da će lijek Ziextenzo za odobrene indikacije djelovati na isti način kao lijek Neulasta u pogledu djelotvornosti i sigurnosti primjene.
English: How does Ziextenzo work?
Croatian: Kako djeluje Ziextenzo?
English: Laboratory studies comparing Ziextenzo with Neulasta have shown that the active substance in Ziextenzo is highly similar to that in Neulasta in terms of structure, purity and biological activity.
Croatian: Laboratorijska ispitivanja u kojima su uspoređivani lijekovi Ziextenzo i Neulasta pokazala su da je djelatna tvar u lijeku Ziextenzo vrlo slična djelatnoj tvari u lijeku Neulasta u pogledu strukture, čistoće i biološke aktivnosti.
English: Ziextenzo is a medicine used in cancer patients to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer treatment and can leave patients vulnerable to infections.
Croatian: Ziextenzo je lijek koji se primjenjuje u bolesnika oboljelih od raka radi ublaživanja neutropenije (niskih razina neutrofila, vrste bijelih krvnih stanica), koja je česta nuspojava pri liječenju raka i koja može dovesti do osjetljivosti bolesnika na infekcije.
English: In addition, studies in breast cancer patients undergoing chemotherapy have shown that the effectiveness of Ziextenzo is equivalent to that of Neulasta in reducing the duration of neutropenia.
Croatian: Nadalje, u ispitivanju provedenom na bolesnicima s rakom dojke koji prolaze kemoterapiju pokazalo se da je lijek Ziextenzo jednako djelotvoran kao i lijek Neulasta u skraćivanju trajanja neutropenije.
English: Studies have also shown that giving Ziextenzo produces similar levels of the active substance in the body to giving Neulasta.
Croatian: Ispitivanja su pokazala i da primjena lijeka Ziextenzo dovodi do slične razine djelatne tvari u tijelu kao i primjena lijeka Neulasta.
English: In Ziextenzo, filgrastim has been ‘pegylated' (attached to a chemical called polyethylene glycol).
Croatian: U lijeku Ziextenzo filgrastim je „pegiliran” (konjugiran s kemijskom tvari naziva polietilenglikol).
English: How is Ziextenzo used?
Croatian: Kako se Ziextenzo primjenjuje?
English: For the full list of side effects and restrictions with Ziextenzo, see the package leaflet.
Croatian: Potpuni popis nuspojava i ograničenja zabilježenih pri primjeni lijeka Ziextenzo potražite u uputi o lijeku.
English: The Agency also noted, however, that there were limited data on the longer-term effects of the medicine and that further data should be provided by the company.
Croatian: Agencija je, međutim, napomenula da postoje ograničeni podatci o dugoročnijim učincima lijeka te da tvrtka treba dostaviti dodatne podatke.
English: Lung function was measured after 4 weeks and 8 weeks of treatment.
Croatian: Funkcija pluća mjerena je nakon četiri tjedna i osam tjedana liječenja.
English: The medicine was also shown to have an acceptable safety profile.
Croatian: Utvrđeno je također da lijek ima prihvatljiv sigurnosni profil.
English: Further information on the orphan designation can be found here: ema.europa.eu/en/medicines/human/orphan-designations/eu308556.
Croatian: Više informacija o statusu lijeka za rijetku bolest možete naći ovdje: ema.europa.eu/en/medicines/human/orphan-designations/eu308556.
English: Further information on Kalydeco can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/kalydeco.
Croatian: Više informacija o lijeku Kalydeco dostupno je na internetskim stranicama Agencije: ema.europa.eu/medicines/human/EPAR/kalydeco.
English: FEV1 is the maximum amount of air a person can breathe out in one second and is a measure of how well the lungs work.
Croatian: FEV1 je najveća količina zraka koju osoba može izdahnuti u jednoj sekundi, a pokazuje koliko dobro funkcioniraju pluća.
English: What measures are being taken to ensure the safe and effective use of Kalydeco?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Kalydeco?
English: They should be mixed with 5 ml of soft food or liquid to make a suspension to be taken by mouth.
Croatian: Granule je potrebno pomiješati s 5 ml mekane hrane ili tekućine kako bi se dobila suspenzija koja se uzima na usta.
English: Kalydeco (ivacaftor)
Croatian: Kalydeco (ivakaftor)
English: What is Kalydeco and what is it used for?
Croatian: Što je Kalydeco i za što se primjenjuje?
English: Other information about Kalydeco
Croatian: Ostale informacije o lijeku Kalydeco
English: Kalydeco is available as tablets (150 mg) and as granules (25, 50, and 75 mg) in a sachet.
Croatian: Lijek Kalydeco dostupan je u obliku tableta (150 mg) i granula (25, 50 i 75 mg) u vrećici.
English: The doses may also need to be adjusted in patients with reduced liver function.
Croatian: Doze će također možda trebati prilagoditi u bolesnika sa smanjenom funkcijom jetre.
English: The European Medicines Agency therefore decided that the benefits of Kalydeco are greater than its risks and it can be authorised for use in the EU.
Croatian: Europska agencija za lijekove stoga je zaključila da koristi od lijeka Kalydeco nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u Europskoj uniji.
English: The doses of Kalydeco may need to be adjusted if the patient is also taking a type of medicine called a ‘moderate or strong CYP3A inhibitor', such as certain antibiotics or medicines for fungal infections.
Croatian: Doze lijeka Kalydeco možda će trebati prilagoditi ako bolesnik uzima i vrstu lijeka „umjereni ili jaki inhibitor CYP3A”, kao što su određeni antibiotici ili lijekovi za gljivične infekcije.
English: The most common side effects with Kalydeco (which may affect more than 1 in 10 people) are headache, sore throat, upper respiratory tract infection (nose and throat infection), nasal congestion, abdominal (belly) pain, nasopharyngitis (inflammation of the nose and throat), diarrhoea, dizziness, rash, bacteria in sputum (phlegm) and an increase in certain liver enzymes.
Croatian: Najčešće nuspojave lijeka Kalydeco (koje se mogu javiti u više od 1 na 10 osoba) jesu glavobolja, grlobolja, infekcija gornjih dišnih putova (infekcija nosa i ždrijela), začepljenje nosa, bol u trbuhu, nazofaringitis (upala nosa i ždrijela), proljev, omaglica, osip, bakterije u ispljuvku (sluzi) te povišenje određenih jetrenih enzima.
English: Side effects reported with Kalydeco are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Kalydeco pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: No difference was seen between placebo and Kalydeco for children aged 6 years and above.
Croatian: Nije opažena razlika između placeba i lijeka Kalydeco za djecu u dobi od šest godina i starijih.
English: Why is Kalydeco authorised in the EU?
Croatian: Zašto je lijek Kalydeco odobren u EU-u?
English: The company that markets Kalydeco is conducting a study in children who were aged 2 to 5 years at the start of treatment to assess long-term effects of early treatment.
Croatian: Tvrtka koja stavlja lijek Kalydeco u promet provodi ispitivanje u djece, koja su na početku liječenja bila u dobi između dvije i pet godina, radi procjene dugoročnih učinaka ranog liječenja.
English: Cystic fibrosis is rare, and Kalydeco was designated an ‘orphan medicine' (a medicine used in rare diseases) on 8 July 2008.
Croatian: Cistična fibroza rijetka je bolest, a lijek Kalydeco dobio je status „lijeka za rijetke bolesti” 8. srpnja 2008.
English: Positive results have also been shown with Kalydeco granules in a study involving 19 children aged 1 to 2 years and 11 children aged 6 months to 1 year.
Croatian: Pozitivni rezultati u vezi s lijekom Kalydeco u granulama utvrđeni su i u ispitivanju koje je obuhvatilo 19 djece u dobi od jedne do dvije godine i 11 djece u dobi od šest mjeseci do jedne godine.
English: For infants and children aged 6 months and above and weighing 5 to 25 kg, the granules should be used.
Croatian: U dojenčadi i djece u dobi od šest mjeseci i starije te tjelesne težine od 5 do 25 kg valja primijeniti granule.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Kalydeco have also been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Kalydeco nalaze se također u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: It should only be prescribed by a doctor with experience in the treatment of cystic fibrosis, and only in patients confirmed to have the mutations mentioned above.
Croatian: Lijek treba propisivati samo liječnik s iskustvom u liječenju cistične fibroze, i to samo bolesnicima kojima su utvrđene prethodno navedene mutacije.
English: One of the studies was in patients aged over 12 years, while the other was in patients aged between 6 and 11 years.
Croatian: U jednom su ispitivanju sudjelovali bolesnici stariji od 12 godina, dok su u drugome sudjelovali bolesnici u dobi od 6 do 11 godina.
English: Kalydeco can only be obtained with a prescription.
Croatian: Kalydeco se izdaje samo na recept.
English: For more information about using Kalydeco, see the package leaflet or contact your doctor or pharmacist.
Croatian: Za više informacija o primjeni lijeka Kalydeco pročitajte uputu o lijeku, odnosno obratite se liječniku ili ljekarniku.
English: The tablets are used in adults and children aged 6 years and above and weighing 25 kg or more.
Croatian: Tablete se primjenjuju u odraslih i djece u dobi od 6 godina i starije, tjelesne težine od najmanje 25 kg.
English: Patients with cystic fibrosis have low bodyweight due to problems with digestion of food and high levels of chloride in sweat due to CFTR not working properly.
Croatian: Bolesnici s cističnom fibrozom imaju malu tjelesnu težinu zbog problema s probavljanjem hrane i visoke razine klorida u znoju zbog nepravilnog djelovanja CFTR-a.
English: As for all medicines, data on the use of Kalydeco are continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Kalydeco kontinuirano se prate.
English: This makes mucus and digestive juices less thick, thereby helping to relieve symptoms of the disease.
Croatian: Sluz i probavni sokovi postaju rjeđi, što pomaže u ublažavanju simptoma bolesti.
English: An overview of Kalydeco and why is it authorised in the EU
Croatian: Pregled informacija o lijeku Kalydeco i zašto je odobren u EU-u
English: Kalydeco received a marketing authorisation valid throughout the EU on 23 July 2012.
Croatian: Lijek Kalydeco dobio je odobrenje za stavljanje lijeka u promet koje je na snazi u EU-u od 23. srpnja
English: What are the risks associated with Kalydeco?
Croatian: Koji su rizici povezani s lijekom Kalydeco?
English: Serious side effects include abdominal pain and increased liver enzymes.
Croatian: Ozbiljne nuspojave uključuju bol u trbuhu i povišenje jetrenih enzima.
English: Kalydeco is a medicine used to treat cystic fibrosis, an inherited disease that has severe effects on the lungs, the digestive system and other organs.
Croatian: Lijek Kalydeco primjenjuje se za liječenje cistične fibroze, nasljedne bolesti koja ima ozbiljne učinke na pluća, probavni sustav i druge organe.
English: The main measure of effectiveness was based on improvement in patients' FEV1.
Croatian: Glavni kriterij učinkovitosti temeljio se na poboljšanju volumena FEV1 u bolesnika.
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Croatian: Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
English: The study found that Kalydeco granules resulted in increased bodyweight and a decreased amount of chloride contained in sweat.
Croatian: U ispitivanju je utvrđeno da je lijek Kalydeco u granulama doveo do povećanja tjelesne težine i smanjenja količine klorida u znoju.
English: The two medicines are used in patients who have inherited the F508del mutation from both parents and therefore have the mutation in both copies of the CFTR gene.
Croatian: Dva se lijeka primjenjuju u bolesnika koji su naslijedili mutaciju F508del od obaju roditelja i stoga imaju mutaciju u objema kopijama gena CFTR.
English: In the studies, Kalydeco was compared with placebo (a dummy treatment).
Croatian: U ispitivanjima je lijek Kalydeco uspoređen s placebom (prividnim liječenjem).
English: The dose and frequency depends on whether Kalydeco is used alone or together with tezacaftor / ivacaftor.
Croatian: Doza i učestalost ovise o tome primjenjuje li se lijek Kalydeco samostalno ili uz tezakaftor/ivakaftor.
English: Kalydeco, taken with tezacaftor / ivacaftor, was compared with placebo.
Croatian: Kalydeco, primijenjen s tezakaftorom/ivakaftorom, uspoređen je s placebom.
English: Kalydeco is used on its own to treat cystic fibrosis in patients aged 6 months and above who have one of nine mutations (changes) in the gene for a protein called ‘cystic fibrosis transmembrane conductance regulator' (CFTR).
Croatian: Lijek Kalydeco primjenjuje se samostalno za liječenje cistične fibroze u bolesnika u dobi od šest mjeseci i starijih koji imaju jednu od devet mutacija (promjena) u genu za bjelančevinu koji se naziva „cistično-fibrozni transmembranski regulator provodljivosti” (CFTR).
English: The first study involved 510 patients with cystic fibrosis who have inherited the F508del mutation from both parents.
Croatian: Prvo je ispitivanje obuhvaćalo 510 bolesnika s cističnom fibrozom koji su naslijedili mutaciju F508del od obaju roditelja.
English: What benefits of Kalydeco have been shown in studies?
Croatian: Koje su koristi od lijeka Kalydeco utvrđene u ispitivanjima?
English: The active substance in Kalydeco, ivacaftor, increases the activity of the defective CFTR protein.
Croatian: Djelatna tvar u lijeku Kalydeco, ivakaftor, povećava aktivnost oštećene bjelančevine CFTR.
English: The second study involved 248 patients with cystic fibrosis who have inherited the F508del mutation from one parent and who also have another CFTR mutation.
Croatian: U drugom je ispitivanju sudjelovalo 248 bolesnika s cističnom fibrozom koji su naslijedili mutaciju F508del od jednog roditelja te koji imaju i drugu mutaciju CFTR-a.
English: Patients who took Kalydeco and tezacaftor / ivacaftor had an average increase in FEV1 of 6.5 percentage points compared with an increase of 4.4 percentage points in patients who took Kalydeco alone and a reduction of 0.3 percentage points in patients who took placebo.
Croatian: Bolesnici koji su uzimali lijek Kalydeco i tezakaftor/ivakaftor imali su prosječno povećanje volumena FEV1 od 6,5 postotnih bodova u usporedbi s povećanjem od 4,4 postotna boda u bolesnika koji su uzimali samo Kalydeco, kao i u usporedbi sa smanjenjem od 0,3 postotna boda u bolesnika koji su uzimali placebo.
English: However, when analysing the subset of patients aged 18 years and above alone, an average improvement of around 5.0 percentage points was seen in patients who took Kalydeco compared with patients who took placebo.
Croatian: Međutim, analizom isključivo potkategorije bolesnika u dobi od 18 godina i starijih opaženo je prosječno poboljšanje od približno 5,0 postotnih bodova u bolesnika koji su uzimali lijek Kalydeco u usporedbi s bolesnicima koji su uzimali placebo.
English: The main measure of effectiveness in these studies was based on improvements in patients' FEV1.
Croatian: Glavni kriterij učinkovitosti u tim ispitivanjima temeljio se na poboljšanju forsiranog izdisajnog volumena FEV1 u bolesnika.
English: Similar results were seen in patients aged between 6 and 11 years, where Kalydeco treatment led to an improvement of 12.5 percentage points more than with placebo.
Croatian: Slični su rezultati opaženi u bolesnika u dobi od 6 do 11 godina, u kojih je liječenje lijekom Kalydeco dovelo do poboljšanja od 12,5 postotnih bodova više nego u bolesnika koji su uzimali placebo.
English: The fourth study involved 69 patients aged 6 years and above with cystic fibrosis who had the R117H mutation.
Croatian: U četvrtom je ispitivanju sudjelovalo 69 bolesnika u dobi od šest godina i više s cističnom fibrozom i mutacijom R117H.
English: Cystic fibrosis affects the cells that produce mucus and digestive juices.
Croatian: Cistična fibroza zahvaća stanice koje proizvode sluz i probavne tekućine.
English: The third study involved 39 patients over 6 years of age with cystic fibrosis due to several mutations other than G551D.
Croatian: U trećem je ispitivanju sudjelovalo 39 bolesnika starijih od 6 godina s cističnom fibrozom koju je uzrokovalo nekoliko drugih mutacija osim mutacije G551D.
English: Kalydeco used on its own or together with tezacaftor / ivacaftor has been shown to improve lung function in patients with specific mutations.
Croatian: Utvrđeno je da lijek Kalydeco, kad se primjenjuje samostalno ili s tezakaftorom/ivakaftorom, poboljšava funkciju pluća u bolesnika sa specifičnim mutacijama.
English: Kalydeco is also used together with another cystic fibrosis medicine containing the active substances tezacaftor and ivacaftor to treat patients with cystic fibrosis aged 12 years and above who have a mutation called F508del in the CFTR gene.
Croatian: Lijek Kalydeco također se primjenjuje s drugim lijekom za liječenje cistične fibroze koji sadržava djelatne tvari tezakaftor i ivakaftor za liječenje bolesnika s cističnom fibrozom u dobi od 12 godina i više s mutacijom naziva F508del u genu CFTR.
English: Kalydeco is also used on its own to treat patients with cystic fibrosis aged 18 years and above who have the R117H mutation in the CFTR gene.
Croatian: Lijek Kalydeco također se primjenjuje za liječenje bolesnika s cističnom fibrozom u dobi od 18 godina i starijih s mutacijom R117H u genu CFTR.
English: They are also used in patients who have inherited the F508del mutation from one parent and also have one of the following mutations in CFTR: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272 26A→G, or 3849+10kbC→T.
Croatian: Također se primjenjuju u bolesnika koji su naslijedili mutaciju F508del od jednog roditelja i ujedno imaju jednu od sljedećih mutacija u genu CFTR: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272 26A→G ili 3849+10kbC→T.
English: Kalydeco contains the active substance ivacaftor.
Croatian: Kalydeco sadrži djelatnu tvar ivakaftor.
English: How does Kalydeco work?
Croatian: Kako djeluje Kalydeco?
English: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, R117H mutations
Croatian: Mutacije G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, R117H
English: The mutations are: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N and S549R (also known as gating mutations).
Croatian: Mutacije su: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N i S549R (također poznate kao mutacije promjene prohodnosti kanala stanične membrane).
English: Two of the studies involved 219 patients with cystic fibrosis who had the G551D mutation.
Croatian: U dvama je ispitivanjima sudjelovalo 219 bolesnika s cističnom fibrozom i mutacijom G551D.
English: After 8 weeks of treatment patients who took Kalydeco had an average improvement of 10.7 percentage points more than those who took placebo.
Croatian: Nakon osam tjedana liječenja bolesnici koji su uzimali lijek Kalydeco imali su prosječno poboljšanje od 10,7 postotnih bodova više od bolesnika koji su uzimali placebo.
English: Another study investigated Kalydeco granules in 34 patients aged between 2 and 5 years of age who had cystic fibrosis due to a G551D or S549N mutation.
Croatian: U drugom ispitivanju, u kojem je ispitivan lijek Kalydeco u granulama, sudjelovala su 34 bolesnika u dobi od dvije do pet godina s cističnom fibrozom uzrokovanom mutacijama G551D ili S549N.
English: For the full list of side effects and restrictions with Kalydeco, see the package leaflet.
Croatian: Potpuni popis svih nuspojava i ograničenja pri primjeni lijeka Kalydeco potražite u uputi o lijeku.
English: After 24 weeks of treatment, patients who took the medicines had an average increase in FEV1 of 3.4 percentage points compared with a reduction of 0.6 percentage points in patients who took placebo.
Croatian: Nakon 24 tjedna liječenja bolesnici koji su uzimali lijekove imali su prosječno povećanje volumena FEV1 od 3,4 postotna boda u usporedbi sa smanjenjem od 0,6 postotnih bodova u bolesnika koji su uzimali placebo.
English: F508del mutation from both parents or F508del mutation from one parent and P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272 26A→G or 3849+10kbC→T mutations
Croatian: Mutacija F508del od obaju roditelja ili mutacija F508del od jednog roditelja i P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272 26A→G ili 3849+10kbC→T mutacije.
English: Kalydeco was shown to be effective at improving lung function in 4 main studies involving patients with cystic fibrosis who had various mutations.
Croatian: U četirima je glavnim ispitivanjima utvrđeno kako je lijek Kalydeco učinkovit u poboljšavanju funkcije pluća u bolesnika s cističnom fibrozom koji su imali razne mutacije.
English: As a result, these secretions become thick and cause blockage.
Croatian: Kao rezultat cistične fibroze, te izlučevine postaju guste i uzrokuju začepljenja.
English: After 24 weeks of treatment, patients aged 12 years and older who took Kalydeco had an average improvement in FEV1 of 10.6 percentage points more than those who took placebo.
Croatian: Nakon 24 tjedna liječenja bolesnici u dobi od 12 godina i stariji koji su uzimali lijek Kalydeco imali su prosječno poboljšanje FEV1 od 10,6 postotnih bodova više od bolesnika koji su uzimali placebo.
English: Kalydeco taken together with tezacaftor / ivacaftor was shown to be effective at improving lung function in two main studies of patients with cystic fibrosis aged 12 years and above with the the F508del mutation.
Croatian: Lijek Kalydeco koji se uzima u kombinaciji s tezakaftorom/ivakaftorom pokazao se učinkovitim u poboljšavanju funkcije pluća u dvama glavnim ispitivanjima u kojima su sudjelovali bolesnici s cističnom fibrozom u dobi od 12 godina i stariji.
English: How is Kalydeco used?
Croatian: Kako se Kalydeco primjenjuje?
English: Kalydeco, taken with tezacaftor / ivacaftor, was compared with Kalydeco taken alone and with placebo.
Croatian: Lijek Kalydeco, koji se primjenjivao u kombinaciji s tezakaftorom/ivakaftorom, uspoređen je s učinkom monoterapije lijekom Kalydeco i učinkom liječenja placebom.
English: Invented nameStrength Pharmaceutical Form Route of Administration
Croatian: Farmaceutski oblik
English: Immediate Packaging Pack size blister (PVC/PVDC/alu) 100 x 1 tablet (unit dose)
Croatian: Za primjenu kroz usta prozirni blisteri s jediničnim dozama (PVC-PVDC/Al)
English: Further information on LysaKare can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/lysakare.
Croatian: Više informacija o lijeku LysaKare dostupno je na internetskim stranicama Agencije: ema.europa.eu/medicines/human/EPAR/lysakare.
English: What is LysaKare and what is it used for?
Croatian: Što je LysaKare i za što se koristi?
English: LysaKare (arginine / lysine)
Croatian: LysaKare (arginin/lizin)
English: What measures are being taken to ensure the safe and effective use of LysaKare?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka LysaKare?
English: Other information about LysaKare
Croatian: Ostale informacije o lijeku LysaKare
English: Because LysaKare can cause nausea (feeling sick) and vomiting, patients will be given medicines to prevent nausea and vomiting before receiving LysaKare.
Croatian: Budući da LysaKare može uzrokovati mučninu (slabost) i povraćanje, bolesnici će primiti lijekove za sprječavanje mučnine i povraćanja prije nego što prime LysaKare.